Australian Regulator Hits Restart on Plan to Name Biosimilars

Australia’s medicines regulator, the Therapeutic Goods Administration (TGA), has announced it will no longer implement a planned update to the way in which it names biosimilar products following a proposal by the World Health Organization to change a naming standard on which Australia relied for its policy.

More at RAPS Regulatory Focus